Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.

Ngo-Giang-Huong N, Wittkop L, Judd A, Reiss P, Goetghebuer T, Duiculescu D, Noguera-Julian A, Marczynska M, Giacquinto C, Ene L, Ramos JT, Cellerai C, Klimkait T, Brichard B, Valerius N, Sabin C, Teira R, Obel N, Stephan C, de Wit S, Thorne C, Gibb D, Schwimmer C, Campbell MA, Pillay D, Lallemant M; EuroCoord-CHAIN-EPPICC joint project study group.

BMC Infect Dis. 2016 Nov 8;16(1):654.

2.

Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses.

Kinloch-de Loes S, Dorrell L, Yang H, Hardy GA, Yerly S, Cellerai C, Vandekerckhove L, De Spielgelaere W, Malatinkova E, Wee Lee Koh W, Johnson MA.

Open Forum Infect Dis. 2015 Nov 23;2(4):ofv144. doi: 10.1093/ofid/ofv144. eCollection 2015 Dec.

3.

Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period.

Aebi-Popp K, Kouyos R, Bertisch B, Staehelin C, Rudin C, Hoesli I, Stoeckle M, Bernasconi E, Cavassini M, Grawe C, Lecompte TD, Rickenbach M, Thorne C, Martinez de Tejada B, Fehr J; Swiss Mother and Child HIV Cohort Study; Swiss HIV Cohort Study.

HIV Med. 2016 Apr;17(4):280-8. doi: 10.1111/hiv.12299. Epub 2015 Aug 12.

PMID:
26268702
4.

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.

Bihl F, Martinetti G, Wandeler G, Weber R, Ledergeber B, Calmy A, Battegay M, Cavassini M, Vernazza P, Caminada AP, Rickenbach M, Bernasconi E; Swiss HIV Cohort Study.

BMC Gastroenterol. 2015 Jul 8;15:79. doi: 10.1186/s12876-015-0308-0.

5.

The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.

Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Kaiser L, Osthoff M, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2014 Aug 24;28(13):1885-9. doi: 10.1097/QAD.0000000000000379.

6.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group.

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
7.

Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.

Wang Q, Young J, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Fehr J, Bucher HC, Battegay M; Swiss HIV Cohort Study.

HIV Clin Trials. 2014 May-Jun;15(3):92-103. doi: 10.1310/hct1503-92.

PMID:
24947533
8.

Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study.

Schäfer J, Young J, Bernasconi E, Ledergerber B, Nicca D, Calmy A, Cavassini M, Furrer H, Battegay M, Bucher H; Swiss HIV Cohort Study.

HIV Med. 2015 Jan;16(1):3-14. doi: 10.1111/hiv.12165. Epub 2014 May 8.

9.

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group.

BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.

10.

The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, Battegay M, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Yerly S, Böni J, Klimkait T, Cellerai C, Günthard HF; Swiss HIV Cohort Study.

PLoS Comput Biol. 2013;9(8):e1003203. doi: 10.1371/journal.pcbi.1003203. Epub 2013 Aug 29.

11.

Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.

Viganò S, Bellutti Enders F, Miconnet I, Cellerai C, Savoye AL, Rozot V, Perreau M, Faouzi M, Ohmiti K, Cavassini M, Bart PA, Pantaleo G, Harari A.

PLoS Pathog. 2013;9(7):e1003423. doi: 10.1371/journal.ppat.1003423. Epub 2013 Jul 4.

12.

Associations between immune depression and cardiovascular events in HIV infection.

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group.

AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3.

PMID:
23842128
13.

Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe.

Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; HIV/TB study group.

Eur Respir J. 2014 Jan;43(1):166-77. doi: 10.1183/09031936.00138712. Epub 2013 Jun 13.

14.

Multicenter evaluation of the Elecsys® anti-HCV II assay for the diagnosis of hepatitis C virus infection.

Esteban JI, van Helden J, Alborino F, Bürgisser P, Cellerai C, Pantaleo G, Eiras A, Rodriguez MI, Ghisetti V, Gleich M, Imdahl R, Kaiser C, Möller P, Wetlitzky O, Segovia M, Schennach H, Mühlbacher A.

J Med Virol. 2013 Aug;85(8):1362-8. doi: 10.1002/jmv.23536.

PMID:
23765774
15.

Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development.

Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group.

PLoS One. 2013 May 29;8(5):e64053. doi: 10.1371/journal.pone.0064053. Print 2013.

16.

Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.

Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C Cohort Study Group.

J Hepatol. 2013 Sep;59(3):504-9. doi: 10.1016/j.jhep.2013.04.032. Epub 2013 May 9.

PMID:
23665287
17.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group.

J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4.

18.

Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.

Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group.

Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206. doi: 10.5588/ijtld.12.0224.

PMID:
23317955
19.

Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients.

Egli A, Schäfer J, Osthoff M, Thiel S, Mikkelsen C, Rauch A, Hirsch HH, Bucher HC, Young J, Jensenius JC, Battegay M, Trendelenburg M; Swiss HIV Cohort Study.

PLoS One. 2013;8(1):e51983. doi: 10.1371/journal.pone.0051983. Epub 2013 Jan 4.

20.

Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS).

Nüesch R, Wang Q, Elzi L, Bernasconi E, Weber R, Cavassini M, Vernazza P, Thurnheer MC, Calmy A, Battegay M, Bucher HC; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):396-404. doi: 10.1097/QAI.0b013e3182847cd0.

PMID:
23288033

Supplemental Content

Loading ...
Support Center